Which Biologics Treat Bullous Pemphigoid and When?

Biologics, such as dupilumab (Dupixent) and rituximab (Rituxan), are advanced, targeted therapies used to treat bullous pemphigoid. These medications are typically considered for patients with moderate-to-severe disease that has not responded to standard treatments, or for those who cannot safely tolerate the side effects of traditional medications ^[1][2].

It is important to understand that these medications have different levels of evidence and regulatory status. In the United States, dupilumab is FDA-approved for moderate-to-severe bullous pemphigoid ^[3]. Other biologics, like rituximab and omalizumab, are generally used “off-label” (prescribed for a condition outside of their official approval) and are supported by varying levels of clinical evidence, primarily for refractory cases ^[4][5]. None of these treatments provide a guaranteed “cure,” but they can help control the disease.

When Are Biologics Considered?

Doctors evaluate the severity of bullous pemphigoid based on factors like the number of ongoing new blisters, the intensity of itching, disruption to sleep and daily function, and how much skin is affected.

Treatment is highly individualized rather than following a rigid step-by-step ladder. High-potency topical corticosteroids (creams or ointments) are the mainstay of treatment ^[1]. When the disease is extensive or topical application is impractical, systemic corticosteroids (oral or injected steroids that affect the whole body) may be used ^[1].

A doctor may consider adding a biologic or a conventional immunosuppressant (like methotrexate or mycophenolate) when:

• The disease is refractory or recalcitrant (it continues to cause blisters despite an adequate trial of standard treatment) ^[1].
• The required dose of steroids is too high and causes serious toxicity.
• The patient has other health conditions that make long-term steroid use unsafe ^[6].

In these situations, biologics can act as steroid-sparing therapies, meaning they help control the disease so the patient can safely and gradually reduce their steroid dose under medical supervision ^[7].

Comparing Biologic Options

Dupilumab (Dupixent)

Dupilumab is given as a subcutaneous (under the skin) injection. It targets specific immune pathways to reduce inflammation.

• Role and Evidence: It is FDA-approved for moderate-to-severe bullous pemphigoid ^[3]. Trial data show that it improves disease control (reducing itch and stopping new blisters) and increases the chance of successfully reducing systemic steroids ^[8][9].
• Safety and Monitoring: Adverse effects can include injection-site reactions, eye inflammation (like conjunctivitis or keratitis), and rare hypersensitivity ^[10]. It can also cause eosinophilia (an elevated level of a specific white blood cell) and infections ^[10]. Routine lab monitoring may vary, but doctors will track clinical response (like itch and blister counts) and potential eye or skin side effects ^[11][10].

Rituximab (Rituxan)

Rituximab is administered via intravenous (IV) infusion. It is a B-cell-depleting therapy; it reduces B cells, which are the immune cells responsible for creating the autoantibodies (harmful proteins) that attack the skin and cause blisters ^[12].

• Role and Evidence: Used off-label, it is typically reserved for severe, refractory, or relapsing cases, or used early alongside steroids for high-risk patients ^[4][13]. It can lead to remission (a period with no new blisters on minimal treatment, as assessed by a doctor), but it may take months to work, and relapses (return of symptoms) can still occur ^[12][14].
• Safety and Monitoring: Rituximab broadly suppresses parts of the immune system. Significant risks include severe infections, infusion reactions, low antibody levels (hypogammaglobulinemia), and delayed drops in white blood cells (neutropenia) ^[12]. It requires strict pre-treatment screening, including Hepatitis B testing (due to the risk of viral reactivation) and complete blood counts (CBC) ^[15]. Vaccination timing is critical, and live vaccines must be avoided during certain periods ^[15].

Omalizumab (Xolair)

Omalizumab is an off-label subcutaneous injection that targets IgE antibodies.

• Role and Evidence: Evidence in bullous pemphigoid is limited, coming mostly from small observational studies and case reports where it is used as an add-on therapy for refractory disease ^[5].
• Safety and Monitoring: It is generally well-tolerated, but it carries a rare but serious risk of severe allergic reaction (anaphylaxis), requiring observation in a clinic after the injection ^[5]. If the medication is stopped, or if steroids are tapered too quickly, the underlying disease can flare up ^[5].

Biologic Medications at a Glance

Important Safety and Practical Guidance

• Never change your treatment on your own: Do not start, stop, or rapidly taper your corticosteroids or biologic medications without direct guidance from your doctor. Stopping steroids abruptly can cause dangerous health complications.
• Seek urgent medical care if you experience:
  • Difficulty breathing, facial swelling, or severe dizziness during or after an injection/infusion.
  • Severe eye pain or sudden changes in vision.
  • Fever, chills, or signs of a serious infection (like rapidly spreading redness, pain, or unusual fatigue).
• Insurance and Access: Because some of these therapies are off-label, insurance approval can be a lengthy process. Discuss financial support programs and the logistics of receiving infusions or injections with your care team.